Bristol-Myers Squibb is a biopharmaceutical company that carries out the discovery and development of transformational medicines for patients suffering from cancer (both solid tumors and hematology), immune disorders, cardiovascular, and neurological disorders. Its pharmaceutical products include small molecule drugs, products produced from biological processes called biologics, and chimeric antigen receptor (CAR) T-cell therapies. The company’s approved products include Revlimid, Eliquis, Opdivo, Pomalyst, Orencia, Sprycel, Yervoy, Abraxane, and Reblozyl, among others.
It concentrates on research and development efforts in disease areas with significant unmet medical needs such as cancer, including immuno-oncology (IO), haematology and cell therapy, including multiple myeloma, lymphoma, and chronic lymphocytic leukaemia, immune disorders including relapsing multiple sclerosis, psoriasis, lupus, rheumatoid arthritis and inflammatory bowel disease, cardiovascular, including cardiomyopathy, heart failure and thrombotic disorders, and fibrotic disease, specifically lung and liver. The company is optimistic about its recent acquisitions such as Celgene and MyoKardia to enhance its presence further in these areas.